RK7 Stock Overview
Engages in the formulation and production of food supplements in Italy. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Laboratorio Farmaceutico Erfo S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.95 |
| 52 Week High | €1.26 |
| 52 Week Low | €0.83 |
| Beta | 1.54 |
| 1 Month Change | -20.67% |
| 3 Month Change | 9.68% |
| 1 Year Change | -20.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| RK7 | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | -20.7% | -1.6% | -2.0% |
| 1Y | -20.7% | -7.6% | 6.8% |
Return vs Industry: RK7 underperformed the German Personal Products industry which returned -7.7% over the past year.
Return vs Market: RK7 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| RK7 volatility | |
|---|---|
| RK7 Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 3.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RK7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine RK7's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 39 | Alessandro Cute | www.erfo.it |
Laboratorio Farmaceutico Erfo S.p.A. engages in the formulation and production of food supplements in Italy. It produces various types of pharmaceutical forms, such as bottles, single-dose vials and bottles, capsules, tablets, and sachets under the Diètnatural and Gianopharma brands, as well as private label brands. The company offers custom formula creation, regulatory advice, graphics, and packaging services.
Laboratorio Farmaceutico Erfo S.p.A. Fundamentals Summary
| RK7 fundamental statistics | |
|---|---|
| Market cap | €10.63m |
| Earnings (TTM) | €441.11k |
| Revenue (TTM) | €5.82m |
24.1x
P/E Ratio1.8x
P/S RatioIs RK7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RK7 income statement (TTM) | |
|---|---|
| Revenue | €5.82m |
| Cost of Revenue | €3.40m |
| Gross Profit | €2.43m |
| Other Expenses | €1.99m |
| Earnings | €441.11k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.052 |
| Gross Margin | 41.68% |
| Net Profit Margin | 7.58% |
| Debt/Equity Ratio | 5.3% |
How did RK7 perform over the long term?
See historical performance and comparisonDividends
4.8%
Current Dividend Yield116%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 18:52 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Laboratorio Farmaceutico Erfo S.p.A. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Federica Fiorenza | KT & Partners Srl |
| Fusun Bektas | KT & Partners Srl |
| Maria Di Grado | KT & Partners Srl |